Imatinib mesylate--a new oral targeted therapy.

By D. Savage, K. Antman. New England Journal of Medicine, 2002

878 citations recorded by the source corpus.

Subfields: Gastroenterology, Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/6583fc0ca67fecb635bb4873e5e9d4fe27032b2a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. C. Ashby
2. Zhesheng Chen

In Hematology

1. E. Scholar
2. C. Ashby
3. Zhesheng Chen
4. A. Arora

Citations in the corpus

• Comparing antibody and small-molecule therapies for cancer (2006, neutral): “gov/cancertopics/types/leukemia">CML ), gastrointestinal stromal tumours (GISTs”
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (2003, neutral): “Symptom improvement rate [95% CI] 44 (43) [33-53] 40 (35) [26-45] 84 (39) [32-45] .”
• Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005, neutral): “Median platelet count, 1000/ L (range) 30 (1-619)”
• Clinical Pharmacokinetics of Imatinib (2005, background): “[1,2] Deregulation of cellular homolog of the viral oncogene v-kit.”
• BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. (2010, background): “Imatinib mesylate (IM, STI-571 or Gleevec), is the first BCR-ABL tyrosine kinase inhibitor (TKI) to be used for the treatment of CML [20].”
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy (2005, background): “Intratumoral and gastrointestinal bleeding developed in fewer than 5% of these patients (Savage and Antman, 2002).”